Optibiomix begins NHS trial on Wellbiome's effect on cardiac surgeries

(Alliance News) - Optibiotix Health PLC on Tuesday said it began a clinical trial to determine the effect of its Wellbiome fibre complex on cardiac surgery outcomes.

The York, England-based life science firm said the study, which will be conducted with Hull University Teaching Hospital NHS Trust, will involve up to 60 patients in a double-blind and placebo-controlled settings.

Those who will receive the mineral-enriched prebiotic fibre complex for six weeks prior to cardiac surgery, will then be evaluated against the baseline on time spent in intensive care, length of hospital stay, and incidence of post-operative complications.

Optibiotix cites multiple studies suggesting a decrease in microbial diversity and abundance post-surgery may increase hospital stays, and as such its product could cause the opposite effect potentially unlocking savings to the UK's National Health Service.

Chief Executive Officer Stephen O'Hara said: "This NHS study by Hull University Hospitals Trust has been designed to evaluate the potential of taking WellBiome as a preoperative supplement on cardiac surgery patients...If successful it could lead to WellBiome becoming the standard of care for NHS patients undergoing surgery".

Optibiomix shares rose 3.7% to 6.48 pence each on Tuesday afternoon in London.

By Martin Miraglia, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2026 Alliance News Ltd. All Rights Reserved.

OptiBiotix Health